Latest News and Press Releases

PharmAla announces that its novel P1 molecule has been accepted by USPTO to its accelerated "Patent Prosecution Highway"

PharmAla releases audited year-end financials for the period ended August 31st.

PharmAla Biotech contracted with Filament Health to manufacture a second batch of MDMA capsules; manufacturing is complete and shipped to clients.

PharmAla partners with Heroic Hearts Canada and the University of Calgary to launch the world's first observational rial into MDMA's real-world efficacy

PharmAla signs long-term partnership with Clariti Strategic Partners as its investment banking and advisory firm

PharmAla completes the historic first shipment of MDMA and Psilocybin to its Australian Joint Venture, Cortexa, for use in commercial patient treatments

PharmAla has recieved a positive First Office Action on its novel P-1 Molecule from the Patent Cooperation Treaty

VANCOUVER, British Columbia, Sept. 06, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTCQB:PMBHF), a biotechnology company focused on the...

VANCOUVER, British Columbia, Aug. 10, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:PMBHF), a biotechnology company focused on the research,...

VANCOUVER, British Columbia, July 31, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:PMBHF), a biotechnology company focused on the research,...